• Earth Science Tech operates through diverse subsidiaries in the CBD space
• The company offers a wide range of CBD products, as well as its MSN-2 medical device
• ETST has varied distribution agreements in place to strengthen its foothold in the CBD marketplace

Earth Science Tech Inc. (OTCQB: ETST) is a biotechnology company operating in varied and vibrant market sectors, including hemp cannabidiol (CBD), nutraceuticals, pharmaceuticals and medical-device research and development. Headquartered in Doral, Florida, the company functions by way of diverse, wholly owned subsidiaries centered on developing its role as a global leader in the CBD space. These subsidiaries are also expanding Earth Science Tech’s work in the pharmaceutical and medical-device sectors.

Earth Science Pharmaceutical Inc. is one of the company’s subsidiaries. Its emphasis is on becoming a worldwide leader in the development of low-cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases) (http://ibn.fm/lrECC). The first medical device offered by Earth Science Pharmaceutical is the MSN-2 Chlamydia Home Kit Screening, designed to detect STIs.

The company’s technology depends on the use of a modified panty liner (MSN-2) worn for four hours to collect a sample of human cells. The liner is then sent to a designated lab, where the cells are subsequently analyzed employing a proven and established process. Modified panty liners have less- strict transport criteria than urine or vaginal swabs. The company is advancing clinical trials of MSN-2 via a collaborative agreement with Laboratories BNK Canada (http://ibn.fm/wnCtn).

Another subsidiary of Earth Science Tech is Cannabis Therapeutics Inc. Cannabis Therapeutics is committed to become a global leader in cannabinoid research and development (R&D) for an extensive line of cannabinoid-based pharmaceuticals, nutraceuticals and other products and solutions. Its mission is to help change the health care landscape by introducing proprietary products made for the global pharmaceutical- and retail-consumer markets.

Cannabis Therapeutics has a provisional application patent for CBD and is invested in R&D to explore and harness the medicinal power of cannabidiol. The company is working to develop CBD-based drugs and nutraceutical products and is also working to integrate CBD molecules with existing generic drug molecules. Cannabis Therapeutics is concentrating on developing pioneering products that provide treatment options for patients and physicians.

Furthermore, Earth Science Tech has its Canna Inno Laboratories Inc. subsidiary. Earth Science Tech established this subsidiary in 2017 to carve out a position in the Canadian province of Québec, giving ETST inside access to the thriving Canadian CBD market. Canna Inno Laboratories provides ETST with access to government grants offered to innovators in the pharmaceutical industry; Canna Inno’s first grant has received approval (http://ibn.fm/veTzP).

Overall, Earth Science Tech offers its unique product lineup in varied forms including liquids, tablets, capsules, soft gels, sprays, chewables, creams, whole herbs and powders. The company’s product family includes CBD oil for pets, flavored and infused CBD oils and a line of organic chocolate CBD products. The company’s CBD oil is 100 percent natural and organic and is manufactured using a supercritical CO2 liquid extraction process.

Earth Science Tech also has key distribution agreements in place to further the market reach of its products. This year, the company signed agreements to distribute CBD products via pharmacies, chiropractors, dispensaries, athletic clubs and clinics (http://ibn.fm/6OWnD). ETST is advancing product placement in large chains, health-food stores and other establishments, and the agreements are for the distribution of a high-grade, full-spectrum cannabinoid line. Agreements are in place with CannaBiz and Desert Sun Distribution.

Moreover, Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to work on projects that scientifically support and advance the health care benefits of the company’s high-grade, hemp-CBD oil.

Earth Science Tech continues to focus on the new frontier involving the innovative integration of CBD with generic drug molecules. With a management team that has decades of invaluable experience in the nutraceutical, dietary supplement, and life sciences sectors, ETST offers investors an attractive opportunity in the emerging CBD space. Earth Science Tech remains dedicated to growing its product portfolio and customer base.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• Supreme Cannabis recently debuted its platform to pursue opportunities in the UK and European CBD health and wellness markets
• The launch comes as Supreme Cannabis continues to advance toward an acquisition of Truverra Inc. and its subsidiary, which sells CBD products in select European markets
• The strategic move provides investors with exposure to the fast-growing European CBD space

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is intensifying its focus on Europe with the launch of London-based investment platform Supreme Heights. In addition, the company’s previously announced acquisition of privately held, Toronto-based Truverra Inc. is expected to close by August 30.

Supreme Heights will better enable Supreme Cannabis to make strategic moves in the CBD health and wellness space in the United Kingdom and Europe. Supreme Cannabis is structured to provide support services for premium brands, as well as CBD offerings (http://ibn.fm/ky5LV).

“Supreme Cannabis is positioned to quickly act on attractive opportunities and establish an early mover advantage in the space,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “Supreme Heights will benefit from our experience launching some of the most premium cannabis brands in Canada and from the strong leadership and the deep industry connections of our UK partners.”

Supreme Heights CEO Patrick Morton said that, with the guidance of Supreme Cannabis, his company would seek to make targeted investments in value-add categories and diverse segments including vaporizers, edibles, beverages, topicals and ancillary services.

In addition to gaining advanced infrastructure and manufacturing capabilities, the acquisition of Truverra offers Supreme Cannabis opportunities to address the international medical market. The companies announced that Truverra would serve as Supreme Cannabis’s global medical brand, building on an existing R&D platform as well as established CBD offerings within Europe.

A Truverra subsidiary, which Supreme Cannabis will also acquire, Netherlands-based Truverra Europe sells hemp-based CBD products in select markets in Europe (http://ibn.fm/ty6Ph). The transaction for 14.7 million common shares of Supreme Cannabis has a value of approximately C$20 million (http://ibn.fm/xwiqW). Truverra Europe will give Supreme Cannabis another distribution point in Europe. These acquisitions support the company’s larger goal of creating new cannabis opportunities across the globe.

Supreme Cannabis is a Toronto-based company focusing on pursuing opportunities and generating sustainable growth in what it sees as an emerging global market. The company’s portfolio includes 7ACRES, an award-winning brand; Blissco, a wellness cannabis brand and licensed producer; Cambium Plant Sciences, a cultivation IP and plant genetics company; Medigrow Lesotho, a Southern Africa cannabis oil producer; Supreme Heights, an investment platform focused on CBD; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• Lionsgate’s Globalgate consortium plays a significant role in the media powerhouse’s efforts at world connectivity through a film-financing structure that harnesses “the upside of international film production”
• Globalgate’s partnership with France’s TF1 Studios marks its 13th partnership aimed at taking advantage of the worldwide boom in local-language features by remaking local hits for non-U.S. markets
• Lionsgate recently launched its first movie-themed amusement park on an island conveniently situated near Macau’s gaming empires and Hong Kong’s international business communities
• The company plans to open a movie-themed park on South Korea’s Jeju Island next year
• China’s amusement park industry is projected to bring in $12 billion in annual revenues by next year

World entertainment content powerhouse Lions Gate Entertainment Corp. (NYSE: LGF.A) (NYSE: LGF.B) continues to build a global, vertically oriented profile offering ways for people to connect with each other and have fun through a variety of innovative platforms. One way that the company is demonstrating its potential for bridging global divides through its revenue-generating activities was manifest in a recent partnership with TF1 Studios, the theatrical division of French commercial television company TF1 Group (http://ibn.fm/zPrk1).

TF1 Studios will provide local French theatrical content for remakes that are primarily marketed to other non-U.S. markets outside France. TF1’s partnership with Lionsgate’s Globalgate content platform grants the local-language film company its 13th curated working production and distribution partner under an umbrella that includes studios such as Mexico’s Televisa, Tobis in Germany, RAI Cinema in Italy and Kadokawa in Japan.

Globalgate uses “a distributor-aligned film-financing structure to harness the upside of international film production” in a variety of foreign markets (http://ibn.fm/GN5ve). The company currently has more than 40 films and series in development, including remakes of Mexican hit Instructions Not Included for the Indian and Korean markets; Argentine romance comedy No Kids for Germany, Korea and Mexico; and Korean action-thriller Terror Live for the Japanese and Indian markets.

“Globalgate has successfully harnessed the fast-growing local content market and their growing roster of blue-chip production and distribution partners is both very compatible with TF1 Studio and will advance our footing in France and globally,” TF1 Studio Deputy CEO Nathalie Toulza Madar stated in a news release.

Lionsgate’s most recent global project is its Lionsgate Entertainment World high-tech, movie-themed amusement park on China’s Hengqin Island, situated near Hong Kong and Macau. The 240,000-square-foot vertically constructed indoor park opened July 31, offering visitors an immersive experience, with 25 attractions built around Lionsgate’s film properties The Hunger Games, Twilight, Divergent, Escape Plan, Now You See Me and Gods Of Egypt (http://ibn.fm/pxaEL).

The amusement park is a key component of the Novotown development, which is focused on non-gaming tourism just across the water from Macau’s “Las Vegas of Asia” casino and shopping attractions, as well as Hong Kong’s nearby international business population. The development itself is part of the Chinese central government’s plan to link the economies of Macau, Hong Kong and major cities in Guangdong Province, where Hengqin Island is located, following suggestions by Macau’s gaming industry that relaxed border formalities between Hengqin and Macau should be encouraged in order to boost tourism trade between the two (http://ibn.fm/peWTP).

Market analysts at World Travel Market anticipate that China’s booming theme park industry could draw revenues of $12 billion by 2020 (http://ibn.fm/fkKez), which would mark an increase of 367 percent from 2010 as the country’s middle income demographic expands.

Movie-themed attractions have long been the focus of tourism agencies in sun-drenched cities, and Lionsgate’s move to join in the market potential grants the company a significant Asian young adult customer base. The company had earlier planned to launch a similar amusement park in New York’s Times Square as the first entry in its strategy of building branded indoor entertainment centers in high-traffic urban areas in major U.S. and European cities, but, in July, Lionsgate announced that it was abandoning the New York site (http://ibn.fm/XIGqd).

The company plans to open its Lionsgate Movie World outdoor theme park on Jeju Island in South Korea next year, and it continues to operate other, smaller theatrical-themed entertainment centers around the world, including live stage attractions such as the Lionsgate Zone of the Motiongate theme park in Dubai, the Saw Escape Room in Las Vegas and the touring Hunger Gamez exhibition.

For more information, visit the company’s website at www.Lionsgate.com

• First Bitcoin Capital is advancing its status as a blockchain tech developer by acquiring the nation’s first bitcoin ATM patent, which it believes controls all bitcoin ATMs and kiosks in the United States
• First Bitcoin is preparing to enforce its patent rights, which it predicts should be worth more than $50 million in profits during the coming five years
• More than 3,000 bitcoin ATMs are currently operating in the United States, and an average of 3.7 bitcoin ATMs are being added each day
• First Bitcoin is also launching an ATM check-cashing service for unbanked payday customers, and it expects to add money order services and bitcoin buying/selling options through a nationwide network of SAMCO kiosks

First Bitcoin Capital Corp. (OTC: BITCF), a blockchain-powered technology developer that has created more than 100 unique cryptocurrencies during its history, is preparing to make a revolutionary leap in its revenue generation following its acquisition of the ‘bitcoin ATM patent’ (http://ibn.fm/COpsb), which it intends to use in governing the more than 3,000 bitcoin ATMs – and growing – operated in the United States.

Bitcoin ATMs are novel machines built on the model of a standard banking ATM, but they allow their users to instantly buy or sell bitcoin and other cryptocurrencies using cash or tokens, without any expectation of a bank account’s involvement in the transaction – although debit and credit cards are accepted.

The patent covers the mechanism that manages the purchase and sale of cryptocurrencies at the kiosks. Industry watcher Coin ATM Radar states that a daily average of 3.7 bitcoin ATM installations were occurring in the United States as of July (http://ibn.fm/ZUJco), and First Bitcoin stated in its news release announcing the acquisition that a business plan prepared by a third party predicts that the patent will bring in more than $50 million in profits over the coming five years.

The company is establishing its strategies for implementing an IP management plan, and it predicts that the patent could have a significant impact on the cryptocurrency industry itself.

“All bitcoin ATMs and kiosks manufactured and sold in the U.S., and all bitcoin ATMs and kiosks operated in the U.S. are believed to be subject to this patent and the company intends to enforce its right upon acquisition of same. The company has already begun negotiations with a major law firm that has a very successful track record in enforcing patent rights when working on a contingency basis,” the news release states (http://ibn.fm/FRYce).

Patenting bitcoin ATMs has been the subject of corporate competition in recent months. DNA Dynamics announced (http://ibn.fm/H3H2D) that it hoped to control “a crucial patent that requires any bitcoin ATM operator to give a royalty on every bitcoin ATM transaction throughout the U.S.,” for example, and Bank of America filed its own statement of interest (http://ibn.fm/4rehC) in technology that uses blockchain to “accelerate transaction speed and/or facilitate other types of transactions in addition to ATM transactions like cash withdrawals and deposits, such as gift registry transactions.”

“Being the first ever publicly traded company in the bitcoin and blockchain industry, we now have acquired one of the most important intellectual properties in this space, as we believe that this patent will provide us a unique and leveraged position, in addition to our other projects as we continue moving forward into the digital asset and cryptocurrency businesses,” First Bitcoin CEO Greg Rubin stated in a news release. “This patent complements our innovation in the field.”

First Bitcoin is developing its ATM presence by launching a pilot test program through which it has ordered Simple Automated Money, Inc. (SAMCO)’s S.A.M. kiosks to integrate bitcoin ATM into self-service check cashing kiosks nationwide, beginning with three kiosks in Northern California. The ATMs will grant unbanked consumers a fast and confidential check-cashing experience through SAMCO’s web-enabled units (http://ibn.fm/HBZSU).

First Bitcoin stated that it is expanding its California dispensary ATM locations to include C-stores and supermarkets. The company announced that it will also begin to add bitcoin buy/sell capabilities through the nationwide network of 85 SAMCO kiosks currently in operation, as well as money order processing and check cashing through touchscreen, biometric-secured access.

For more information, visit the company’s website at www.FirstBitcoin.io

• INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston
• Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of a combination immunotherapy to potentially reverse resistance to treatment
• The annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides unique opportunities to connect scientists with the latest discoveries in the field

An international mix of thought leaders and decision makers from the international immunotherapy and immuno-oncology community are gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ Tesi slated to deliver several presentations. A news release outlining Tesi’s agenda at the five-day Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit highlights INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease (http://ibn.fm/4pBdZ).

“We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” Tesi stated in a news release. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.”

A fast-growing cancer patient population that is resistant to checkpoint inhibitors (“CPI”) was the focus of Tesi’s presentation on Monday, August 5, under the title ‘Targeting Soluble TNF to Improve Efficacy of Combination Immunotherapy’. During his presentation, Tesi reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients (http://ibn.fm/m1Iy3).

“The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,” continued Tesi, who is also INmune Bio’s chief medical officer. “All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.”

The Phase I trial is an open-label, dose-escalation trial in patients with advanced solid tumors. Patients received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by leveraging a dominant-negative technology. Positive preliminary data from the first two cohorts were released. That data will be followed by a final report later this year as the company advances the program into a Phase II study.

Tesi is also speaking on ‘Next-Generation Immunotherapies’ and ‘Targeting ‘Protector’ Cells of the Innate Immune System’ during the summit. The Cambridge Healthcare Institute’s annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides a unique opportunity to network with decision-makers, build lasting collaborations and gain actionable solutions.

INmune Bio also recently attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan, where Tesi gave a talk titled ‘Combination Immunotherapy to Overcome Resistance to Cancer Treatments’. His presentation centered on monotherapy with checkpoint inhibitors (“CPI”) as an effective treatment option. The combination of CPI and other therapies may improve outcomes in patients who are unresponsive to monotherapy, an article explains (http://ibn.fm/EFAdX).

INmune Bio’s product pipeline targets three segments of concern: Alzheimer’s disease/dementia, which claims 5.5 million patients in the U.S.; cancer residual disease, which is expected to generate more than 1.7 million new cases yearly; and resistance to immunotherapy. INmune Bio is currently working on three product platforms: INKmune and INB03, which modify a patient’s innate immune response to cancer; and XPro1595, which targets inflammation linked to Alzheimer’s disease.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• Financial results for the second quarter of 2019 have Trxade Group’s managerial team optimistic about the future of the brand and its digital platforms
• The company already has over 10,500 members for its pharmacy trading platform
• Independent pharmacies face many challenges when it comes to securing cost-efficient drugs, and Trxade Group has the technology to address these issues and continue building new industry-relevant products in the future

Trxade Group Inc. (OTCQB: TRXD), an integrated pharmaceutical logistical service company, expects its new product lines to generate profitability in the coming months of 2019 and beyond, CEO and chairman Suren Ajjarapu said after the company announced its financial results for the second quarter of 2019.

“In response to customer demand, we are actively developing new product offerings with increased data analytics capability which will help independent pharmacies better manage their inventory and costs,” Ajjarapu stated in a company news release (http://ibn.fm/aprPi).

Trxade Group brings together web-based purchasing platforms for independent pharmacy and drug manufacturer transactions, a mail order pharmacy E-Hub and warehouse and drug delivery services for consumers across the U.S. For the quarter ended June 30, 2019, the company registered record revenue of $1,916,414, marking a massive increase from the $837,688 reported for the same period of 2018. In addition, gross profits for the three-month period went up to $1,163,276 from $837,688 in 2018. Operating income also went up. The company attributed this growth to its independent pharmacy acquisition. These results marked the eighth consecutive quarter during which the Trxade platform reported record quarterly operating costs.

By the end of June 2019, Trxade had registered 390 new independent pharmacies via the platform, marking an increase of 24 percent from the previous quarter and 137 percent on an annual basis. In addition, the company’s consumer app, www.Delivmeds.com, added 94 new independent pharmacies to expand the B2C delivery network of the platform.

Through the network increase achieved in the second quarter of 2019, membership for the TRXD trading software has gone up to 10,500 pharmacies. There are over 24,000 independent pharmacies in the U.S., and their combined pharmaceutical purchase capabilities exceed $93 billion per year.

Many independent pharmacies in the U.S. are limited in terms of time and resources for the purchase of medications. These pharmacies often struggle to maintain margins, which has made them turn to sourcing programs and other opportunities in the past to reduce the purchase cost of drugs. Rising fees and reduced reimbursements, however, have contributed to declining margins for independent pharmacies over the past decade.

Trxade Group offers independent pharmacies a real opportunity to reduce purchase costs while also benefiting from a fully integrated web service. The Trxade platform (Trxade Exchange) isn’t just there to facilitate the cost-efficient acquisition of drugs; it also creates a network of associated pharmacies and gives smaller industry representatives access to a wider supply chain network. This way, pharmacies can view different products and manufacturers, buying groups and wholesalers on a real-time basis.

The size of the industry and the exceptional financial results that Trxade Group registered in the second quarter of 2019 have the company’s managerial team optimistic about the future of both B2B and B2C pharmaceutical service provision.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Lexaria’s patented DehydraTECH technology improves taste, achieves higher absorption rates and promotes fast onset of bioactive compounds, including nicotine and cannabinoids
• Nine corporate licensees have signed a total of 11 definitive contracts to use DehydraTECH technology in innovative beverages, edibles and oral products
• Lexaria expects to experience unprecedented revenue growth as many of its clients plan aggressive rollouts and growth for their product lines

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is expanding its family of existing licensees and partners with an impressive lineup of new corporate licensees for use of Lexaria’s patented DehydraTECH absorption technology. A total of nine corporations have signed 11 definitive contracts to use Lexaria’s revolutionary DehydraTECH drug delivery platform within their existing and emerging brands, as the company detailed in a recent news release (http://ibn.fm/tkN6e).

“The first half of 2019 delivered a period of unprecedented achievements for Lexaria,” CEO Chris Bunka stated in a news release. “We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous. We also launched our brand-new business division Lexaria Nicotine which is disrupting nicotine delivery methods that already attracted one of the world’s largest nicotine companies, which has licensed our technology.”

Lexaria recently announced that it has discovered improved performance characteristics in a new version of its DehydraTECH delivery platform. An innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance, the company stated in a news release (http://ibn.fm/9sZRc), making the technology suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical and supplement markets. New patent applications related to the recent innovations have been filed.

Lexaria credits its recent commercial success mainly to its ever-growing body of scientific results evidencing the superior capabilities and power of its patented technologies. Recent technological advancements are the result of one of the industry’s most focused and productive R&D programs and hold promise for even higher levels of performance. In one 2019 animal study, combining Lexaria’s DehydraTECH with nanotech technologies delivered increased quantities of CBD into brain tissue following oral ingestion than certain existing industry formulations (http://ibn.fm/vWbd5).

Among the companies taking notice of Lexaria’s DehydraTECH drug delivery platform by signing new license contracts are:

• Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group Inc., for oral nicotine products; this license is signed with Lexaria Nicotine LLC, a separate business division of Lexaria Bioscience Corp;
• Nuka Enterprises LLC, for a new CBD/hemp license for beverages across the U.S.;
• Two new worldwide beverages licenses to Hill Street Beverages (excluding Mexico);
• Two new joint manufacturing production licenses with Hill Street Beverages for new, jointly owned cannabis and CBD brands;
• Three new licenses with other companies for CBD beverages and edible CBD ingredients/products across the U.S.;
• One new license for cannabis beverages in California; and
• One new multistate cannabis expansion license with Nuka Enterprises LLC for its 1906 Brands for five states and two new product categories.

Lexaria expects to sign additional new definitive license agreements through the balance of 2019 and beyond as demand for its industry-leading technology continues to increase. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and Australia for utilization of its DehydraTECH delivery technology.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Grapefruit recently filed a registration statement with the SEC
• The company is one of the earliest registered cannabis distribution firms to attain an annually renewable license
• Following the registration statement, Grapefruit’s second funding tranche is expected to be released this week

California-based Grapefruit Boulevard Investments Inc. (OTCQB: IGNG), a fully licensed premier cannabis manufacturer and distributor in the California legal cannabis marketplace, has filed a registration statement with the SEC on Form S-1 to register shares of the company’s common stock underlying the $600,000 convertible note recently issued to an institutional investor, as well as other securities to be issued to the investor (http://ibn.fm/K86Ke). This filing is an important achievement for Grapefruit in its quest to become a premier cannabis company, boasting quality control and attention to detail from production to distribution.

Headquartered in Los Angeles, California, Grapefruit holds licenses to both manufacture and distribute cannabis products. It also has its own branded product lines. The company is well focused on sourcing only the best-of-the-best raw cannabis materials in its mission to create the highest-quality, most trusted and most consistent recreational and medical cannabis products for its customers.

Despite its booming scale, the cannabis industry is not without its challenges. In 2018, the legal cannabis industry experienced one of its slowest annual expansion rates since Colorado launched the adult-use era in 2014. In California, legal spending on cannabis fell from $3 billion in 2017 to $2.5 billion during the year in which the state implemented an adult-use regulatory regime. A key takeaway from the California market is that highly restrictive regulations and high tax rates may be hurting the legal market’s ability to compete with the illicit market (http://ibn.fm/Gupy0). However, Grapefruit is poised with an industry advantage as one of the few vertically integrated cannabis companies.

Grapefruit holds its State of California provisional licensing from the Bureau of Cannabis Control and the California Department of Public Health. The company is one of the earliest registered distribution companies with the state to have an annually renewable license, as opposed to the temporary licenses previously granted.

The regulatory changes have impacted the ability of new businesses to enter the marketplace and compete with Grapefruit. However, none of Grapefruit’s commercial cannabis businesses have been impacted by the regulatory changes to the marketplace. Grapefruit understands the state’s regulatory burdens and is fully compliant with all applicable laws and regulations.

Now that Grapefruit has filed a registration statement, it is well-positioned to experience significant growth. The investor is required to fund the second tranche of $1.4 million in accordance with the terms of the securities purchase agreement. Grapefruit anticipates that the second tranche will be funded this week.

“The filing of the registration statement is the timely achievement of yet another publicly stated goal of the company,” Grapefruit CEO Bradley J. Yourist stated in a news release. “Moreover, the infusion of an additional $1,400,000.00 of capital will allow IGNG/Grapefruit to, as expeditiously as possible, exploit significant revenue opportunities available to it and to move forward with its business plan as we move inexorably toward our goal of becoming the leading fully integrated, licensed and compliant cannabis product manufacturing and distribution company.”

Yourist concluded, “We are pleased that another important box has been checked on time.”

Grapefruit’s goal is to become a vertically integrated, seed-to-sale cannabis and CBD product company serving the California market. Moreover, the company plans to roll out its product lines in other states, including Nevada, Illinois, Oregon, Colorado and Washington. Grapefruit’s motto – ‘A High You Can Trust’ – embodies its philosophy and ethos, reminding consumers of the company’s commitment to manufacture, procure and distribute only the highest-quality, all-natural cannabis flower, concentrates and products.

Grapefruit Boulevard Investments is a wholly owned subsidiary of Imaging3.

For more information, visit the company’s website at www.GrapefruitBlvd.com

NOTE TO INVESTORS: The latest news and updates relating to IGNG are available in the company’s newsroom at http://ibn.fm/IGNG

• Lexaria Bioscience’s revolutionary DehydraTECH technology enables cannabis consumers to experience rapid-on, rapid-off effects in non-smoked formulations
• A just-announced joint manufacturing partnership between Lexaria and alcohol-free beverage maker Hill Street Beverage Company is paving the way for wider distribution of Lexaria’s platform
• Hill Street is the only company to have gained licenses to use DehydraTECH on a global basis, taking advantage of Lexaria’s multiple international granted and pending patents
• By 2024, cannabis-infused beverage sales are expected to rise by nearly 15 times from last year’s revenues of $89 million

The exploding interest in cannabis products and in new ways of enjoying them has proven fertile ground for drug technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) as it markets the company’s revolutionary DehydraTECH platform for increasing the absorption rates of varied edible substances, including nicotine and cannabidiol (CBD).

DehydraTECH is a drug delivery technology that gets ingested active pharmaceutical ingredient (API) molecules to the bloodstream faster than other methods. Under a new agreement announced July 24, the company will expand DehydraTECH’s reach by allowing Hill Street Beverage Company Inc. (TSX.V: BEER), a manufacturer of alcohol-free and cannabis-infused beer, wine, and adult format beverages, to produce commercial products in partnership with Lexaria under a new brand that is yet to be announced (http://ibn.fm/BTodZ).

The new brand will include processed tetrahydrocannabinol (THC) and/or cannabidiol (CBD) powder ingredients from cannabis for the Canadian market. The agreement will be in force for 10 years. Both companies expect the arrangement to create the potential of enhanced cashflow, and Lexaria, in particular, is anticipated to benefit from the emerging federally legal cannabis edibles industry in Canada, where edible cannabis products will be allowed under new laws beginning in October.

The new joint manufacturing partnership will create a mechanism for intermediate ingredients made from DehydraTECH-processed cannabis and hemp powders to be sold for the first time on a business-to-business (B2B) basis between Canada’s licensed producers and other businesses licensed by Health Canada to make cannabis-infused edibles. The powders are stable, with a two-to-three-year shelf life, and are odorless and tasteless, providing a full-spectrum cannabis experience for nearly any ingestible product format.

“When we first began our relationship with Lexaria it was based on a comprehensive competitive review of the market with a single uncompromising vision: to find a technology partner who could provide water soluble cannabis, with zero impact on the award-winning taste and aroma of our products,” Terry Donnelly, chairman and CEO of Hill Street, stated in a news release. “This partnership takes our relationship to a whole new level, which we believe will help to set a global standard for excellence that consumers are looking for in cannabis edibles and beverages.”

In addition to the rapid onset of ingested cannabis’ effect enabled by DehydraTECH, the technology creates a mechanism for stronger peak delivery of the effect through higher peak blood concentrations, as demonstrated in third-party lab tests. The technology also delivers the benefit of a “fast-off” effect, with the initial peak followed four hours later by lower cannabinoid content in the blood than some competitors’ nanotech-enabled formulations, leading to a shorter-duration experience that many consumers prefer as they resume other activities.

Hill Street is the only company to gain semi-exclusive licenses to use the DehydraTECH CBD beverage infusion technology in global markets around the world. DehydraTECH has received 11 patents in the United States and Australia and has about 60 additional patents pending in more than 40 countries worldwide.

Food and drink consultancy Zenith Global predicts that the U.S. market for cannabis- and hemp-infused drinks will balloon by nearly 15 times last year’s revenues of $89 million to over $1.4 billion by 2024 (http://ibn.fm/PgbKH).

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Prelaunch of the company’s cannabis delivery service, Viva Buds Inc., was recently announced, with signups now being accepted as the official August launch date nears
• MCOA’s revolutionary, nourishing cosmetic topical CBD formula, hempSMART Body Cream, is designed to set a new industry standard by helping to improve overall skin health
• The company’s expansion of wholly owned subsidiary hempSMART Ltd. into Europe continued with its recent entry into the Netherlands

Marijuana Company of America Inc. (OTCQB: MCOA), an innovative hemp and cannabis corporation, continues to expand its portfolio with new products and avenues of customer service. As pioneers in the cannabis industry, dating back to 2009 when MCOA CEO Don Steinberg founded the first marijuana company ever to trade on a U.S. stock market (Medical Marijuana Inc.), MCOA has stayed at the forefront of the cannabis and hemp industry.

The establishment of a joint venture with Natural Plant Extract of California (“NPE”), along with a 20 percent ownership stake in the company, led to the creation of Viva Buds Inc., a unique, Los Angeles, California-based cannabis delivery service. MCOA’s commitment to the joint venture is evident in a recent news release (http://ibn.fm/rLE91) announcing the acceptance of potential customers during a prelaunch of Viva Buds’ cannabis delivery service in the San Fernando Valley in the Los Angeles area.

Interested adult consumers can sign up now at www.VivaBuds.com, which will give customers several advantages before the official August 2019 launch date, including the ability to build their own personal cannabis business utilizing a “call your friend” approach (http://ibn.fm/mIiIY).

The joint venture calls for MCOA and NPE to share in the net profits on a 50-50 basis, with NPE managing all operations pertaining to distribution, manufacturing and delivery of cannabis products, while MCOA provides capital, consulting and marketing services. “It’s an innovative opportunity in one of the largest U.S. markets for recreational cannabis,” Steinberg said in a news release.

MCOA’s hempSMART brand is also launching a revolutionary, nourishing topical CBD-infused cosmetic product called hempSMART Body Cream (http://ibn.fm/VWB5S). Each bottle of hempSMART Body Cream is formulated with 300 mg of organically grown, full spectrum, non-psychoactive cannabidiol derived from industrial hemp.

“Combining premium CBD oil with a unique blend of synergistic Ayurvedic herbs and botanicals illustrates a major advancement in the wellness arena,” added Paula Vetter, a holistic nurse practitioner and certified herbalist who is also chair of the hempSMART medical advisory board. “The cream is completely free of toxins that are commonly found in many skin care products and absorbed through the skin and into the blood stream… Instead, hempSMART’s Body Cream is a topical wellness solution that sets a new standard in the industry by improving the overall health of skin with each use.”

The hempSMART product line distinguishes itself from competitors through its premier quality extracts derived from industrial hemp plants grown specifically to provide the highest concentration of CBD. In fact, hempSMART products received such positive feedback during a launch in the United Kingdom in March 2019 that MCOA was encouraged to expand its European footprint into the Netherlands through its wholly owned subsidiary, hempSMART Ltd., in June 2019 (http://ibn.fm/7p9YG).

“The Netherlands launch was a complete success, with people traveling from other parts of Europe to witness the excitement around our hempSMART CBD product line,” Ian Harvey, global sales director of hempSMART, noted. “The event featured our CEO, Don Steinberg, unveiling our wellness products via video link and educating people about the benefits of our prime quality botanical ingredients. Our products sold out at the end of the event, and we engaged new marketing associates for hempSMART as evangelists to the brand that will help spread our vision.”

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA